Newly designed large cell Niti-S stent for malignant hilar biliary obstruction: a pilot study

Kogure, Hirofumi; Isayama, Hiroyuki; Nakai, Yousuke; Tsujino, Takeshi; Ito, Yukiko; Yamamoto, Keisuke; Yagioka, Hiroshi; Kawakubo, Kazumichi; Sasaki, Takashi; Hirano, Keisuke; Sasahira, Naoki; Tada, Minoru; Omata, Masao; Koike, Kazuhiko

doi:10.1007/s00464-010-1194-8

Cited by 62 publications

(77 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We investigated papers about hilar obstruction due to malignant biliary stricture including HCC and cholangiocarcinoma (table 1) [10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]. The successful drainage rate ranges from 72 to 100%.…”

Section: Drainagementioning

confidence: 99%

Hepatocellular Carcinoma with Obstructive Jaundice: Endoscopic and Percutaneous Biliary Drainage

Minami

Kudo²

2012

Dig Dis

View full text Add to dashboard Cite

Among patients with later stage hepatocellular carcinoma (HCC), only 1–12% manifest obstructive jaundice as the initial complaint. Endoscopic retrograde biliary drainage (ERBD) and percutaneous transhepatic biliary drainage (PTBD) are the two main non-surgical treatment options for obstructive jaundice in patients with HCC. ERBD is usually the first-line treatment because of its low hemorrhage risk. Some have reported that the successful drainage rate ranges from 72 to 100%. Mean stent patency time and mean survival range from 1.0 to 15.9 and 2.8 to 12.3 months, respectively. PTBD is often an important second-line treatment when ERBD is impossible. With regard to materials, metallic stents offer the benefit of longer patency than plastic stents. The dominant effect of biliary drainage suggests that successful jaundice therapy could enhance anti-cancer treatment by increasing life expectancy, decreasing mortality, or both. We present an overview of the efficacy of endoscopic and percutaneous drainage for obstructive jaundice in patients with HCC who are not candidates for surgical resection and summarize the current indications and outcomes of reported clinical use.

show abstract

Section: Drainagementioning

confidence: 99%

Hepatocellular Carcinoma with Obstructive Jaundice: Endoscopic and Percutaneous Biliary Drainage

Minami

Kudo²

2012

Dig Dis

View full text Add to dashboard Cite

show abstract

“…Bilateral SEMS stenting can be performed using the SIS or SBS technique. In the SIS technique, the second SEMS is inserted to the contralateral hepatic duct through the mesh of the first SEMS [16][17][18][19][20][21][22]. Conversely, in the SBS technique, two SEMSs are inserted parallel to each other into the right and left hepatic duct [23][24][25][26] (Fig.…”

Section: Multiple Stenting Methods (Stent-in-stent or Side-by-side)mentioning

confidence: 99%

“…To overcome this hurdle, a large open-cell wire mesh SEMS (Niti-S large cell D-type; Taewoong Corp., Seoul, Korea) was developed. Kogure et al [20] demonstrated high technical success rates with large-cell SEMSs in the bilateral SIS technique. A newly designed, closed-cell and cross-wire stent is another SEMS (Bonastent M-Hilar; Standard Sci Tech Inc., Seoul, Korea) dedicated to SIS stenting, which comprises a hook and cross-wired structure on the proximal and distal portions, and only the cross-wired structure on the central portion facilitates the SIS technique [17].…”

Section: Progress Of Sems For Bilateral Stentingmentioning

confidence: 99%

Endoscopic biliary stenting for unresectable malignant hilar obstruction

Fukasawa

Takano

Shindo

et al. 2017

Clin J Gastroenterol

View full text Add to dashboard Cite

“…Median stent patency was 202 days. 69 Although the results were comparable with unilateral and bilateral side-by-side stent placement, Kogure and others have demonstrated good success with the stent-in-stent method.…”

mentioning

confidence: 85%

“…Kogure et al examined the feasibility and efficacy of this large mesh stent for both unilateral and bilateral drainage of malignant hilar biliary obstruction. 69 Twelve patients first underwent unilateral or bilateral drainage using a plastic stent or nasobiliary drainage tube. If jaundice improved, the plastic stent or drainage tube was replaced with a unilateral large mesh biliary stent; and if jaundice did not improve, bilateral large mesh stents were placed.…”

mentioning

confidence: 99%

An Update to Hepatobiliary Stents

Moy¹,

Bir²

2015

JCTH

View full text Add to dashboard Cite

Endoscopic stent placement is a common primary management therapy for benign and malignant biliary strictures. However, continuous use of stents is limited by occlusion and migration. Stent technology has evolved significantly over the past two decades to reduce these problems. The purpose of this article is to review current guidelines in managing malignant and benign biliary obstructions, current endoscopic techniques for stent placement, and emerging stent technology. What began as a simple plastic stent technology has evolved significantly to include uncovered, partially covered, and fully covered self-expanding metal stents (SEMS) as well as magnetic, bioabsorbable, drug-eluting, and antireflux stents.

show abstract

Newly designed large cell Niti-S stent for malignant hilar biliary obstruction: a pilot study

Abstract: The newly designed endoscopic metallic stent may be feasible and effective for malignant hilar biliary obstruction, and endoscopic reintervention is relatively simple.

Cited by 62 publications

References 18 publications

Hepatocellular Carcinoma with Obstructive Jaundice: Endoscopic and Percutaneous Biliary Drainage

Hepatocellular Carcinoma with Obstructive Jaundice: Endoscopic and Percutaneous Biliary Drainage

Endoscopic biliary stenting for unresectable malignant hilar obstruction

An Update to Hepatobiliary Stents

Contact Info

Product

Resources

About